Bullish: Analysts Just Made A Huge Upgrade To Their Health In Tech, Inc. (NASDAQ:HIT) Forecasts

Shareholders in Health In Tech, Inc. (NASDAQ:HIT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance. Health In Tech has also found favour with investors, with the stock up a noteworthy 21% to US$1.64 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the upgrade, the current consensus from Health In Tech's twin analysts is for revenues of US$33m in 2025 which - if met - would reflect a major 23% increase on its sales over the past 12 months. Per-share earnings are expected to accumulate 3.5% to US$0.025. Previously, the analysts had been modelling revenues of US$29m and earnings per share (EPS) of US$0.015 in 2025. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.

Check out our latest analysis for Health In Tech

With these upgrades, we're not surprised to see that the analysts have lifted their price target 43% to US$3.25 per share.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Health In Tech's rate of growth is expected to accelerate meaningfully, with the forecast 51% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 30% over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 5.5% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Health In Tech to grow faster than the wider industry.

The Bottom Line

The biggest takeaway for us from these new estimates is that analysts upgraded their earnings per share estimates, with improved earnings power expected for this year. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Given that the consensus looks almost universally bullish, with a substantial increase to forecasts and a higher price target, Health In Tech could be worth investigating further.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2027, which can be seen for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.